Skip to content

Released Mar 17, 2025, before the open

10-K filed Mar 17, 2025, 76 days after period end · 0001558370-25-003039

Q4 2024 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$18.22Mderived+73.7% vs Q4 2023+1.4% vs Q3 2024
Net Income$6.49MderivedN/M vs Q4 2023+100.7% vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$7,209,000N/M
Operating Cash Flowderived$3,991,000+11.0%
Free Cash Flowderived$3,566,000+6.6%
Margins · derived
Operating margin39.6%+93.1 pt vs Q4 2023
Net margin35.6%+93.3 pt vs Q4 2023

What the release said

The release

Same quarter

MetricQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figures
Revenue$18.22M$10.49M$8.62M$8.55M
Net Income$6.49M-$6.04M-$3.74M-$6.67M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR